BR0308229A - Medicamentos contendo ingredientes ativos que diminuem o nìvel de colesterol com liberação do ingrediente ativo de tempo tardio - Google Patents

Medicamentos contendo ingredientes ativos que diminuem o nìvel de colesterol com liberação do ingrediente ativo de tempo tardio

Info

Publication number
BR0308229A
BR0308229A BR0308229-6A BR0308229A BR0308229A BR 0308229 A BR0308229 A BR 0308229A BR 0308229 A BR0308229 A BR 0308229A BR 0308229 A BR0308229 A BR 0308229A
Authority
BR
Brazil
Prior art keywords
active ingredient
release
cholesterol level
medicines
lower cholesterol
Prior art date
Application number
BR0308229-6A
Other languages
English (en)
Inventor
Peter Kraass
Original Assignee
Ratiopharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm Gmbh filed Critical Ratiopharm Gmbh
Publication of BR0308229A publication Critical patent/BR0308229A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Abstract

"MEDICAMENTOS CONTENDO INGREDIENTES ATIVOS QUE DIMINUEM O NìVEL DE COLESTEROL COM LIBERAçãO DO INGREDIENTE ATIVO DE TEMPO TARDIO". A presente invenção refere-se a um medicamento contendo pelo menos um ingrediente ativo que diminui o colesterol no sangue, caracterizado pelo fato de que possui meios para fornecer características de liberação para o ingrediente ativo com as quais o ingrediente ativo é liberado com pelo menos duas taxas diferentes de liberação, especificamente com uma primeira taxa de liberação em um primeiro período e com uma segunda taxa de liberação, que é mais elevada do que a primeira taxa de liberação, em um segundo período subsequente, onde o segundo período se inicia de 2 a 12 horas após a administração do medicamento.
BR0308229-6A 2002-03-07 2003-03-06 Medicamentos contendo ingredientes ativos que diminuem o nìvel de colesterol com liberação do ingrediente ativo de tempo tardio BR0308229A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10209979A DE10209979A1 (de) 2002-03-07 2002-03-07 Arzneimittel mit Cholesterolspiegel-senkenden Wirkstoffen mit zeitverzögerter Wirkstofffreisetzung
PCT/EP2003/002328 WO2003074034A1 (de) 2002-03-07 2003-03-06 Arzneimittel mit cholesterolspiegel-senkenden wirkstoffen mit zeitverzögerter wirkstofffreisetzung

Publications (1)

Publication Number Publication Date
BR0308229A true BR0308229A (pt) 2004-12-28

Family

ID=27771068

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308229-6A BR0308229A (pt) 2002-03-07 2003-03-06 Medicamentos contendo ingredientes ativos que diminuem o nìvel de colesterol com liberação do ingrediente ativo de tempo tardio

Country Status (11)

Country Link
US (1) US20050203186A1 (pt)
EP (1) EP1480623A1 (pt)
JP (1) JP2005526739A (pt)
AU (1) AU2003218701A1 (pt)
BR (1) BR0308229A (pt)
CA (1) CA2478425A1 (pt)
DE (1) DE10209979A1 (pt)
NO (1) NO20044132L (pt)
PL (1) PL372720A1 (pt)
RU (1) RU2004127193A (pt)
WO (1) WO2003074034A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1563837A1 (en) * 2004-02-03 2005-08-17 Ferrer Internacional, S.A. Hypocholesterolemic compositions comprising a statin and an antiflatulent agent
AU2005247195A1 (en) * 2004-05-27 2005-12-08 Dexcel Pharma Technologies Ltd Localized controlled absorption of statins in the gastrointestinal tract for achieving high blood levels of statins
ES2539969T3 (es) * 2004-08-25 2015-07-07 Essentialis, Inc. Formulaciones farmacéuticas de activadores del canal de potasio de ATP y usos de las mismas
EP1817010A4 (en) * 2004-11-22 2009-06-17 Dexcel Pharma Technologies Ltd CONTROLLED ABSORPTION OF STATINS IN THE INTESTINE
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
PL1968601T3 (pl) 2006-01-05 2012-03-30 Essentialis Inc Sole związków otwierających kanały potasowe ATP i ich zastosowanie
US7427414B2 (en) * 2006-01-18 2008-09-23 Astron Research Limited Modified release oral dosage form using co-polymer of polyvinyl acetate
DE102006006532B4 (de) * 2006-02-10 2007-11-08 Biogenerics Pharma Gmbh Pharmazeutische Zubereitung
EP1818050A1 (de) * 2006-02-10 2007-08-15 Stada Arzneimittel Ag Stabile pharmazeutische Zusammensetzungen umfassend einen HMG-CoA-Reduktase Inhibitor
EP1825848A3 (de) * 2006-02-10 2010-03-03 Stada Arzneimittel Ag Stabile pharmazeutische Zusammensetzungen umfassend einen HMG-CoA-Reduktase Inhibitor
FR2904225B1 (fr) * 2006-07-28 2010-08-13 Bouchara Recordati Compositions pharmaceutiques de substances actives difficilement detournables de la voie d'administration a laquelle elles sont destinees
WO2009006483A1 (en) * 2007-07-02 2009-01-08 Essentialis, Inc. Salts of potassium atp channel openers and uses thereof
US20110003837A1 (en) * 2008-01-30 2011-01-06 Lupin Limited Modified release formulations of hmg coa reductase inhibitors
KR101298788B1 (ko) * 2011-03-15 2013-08-22 보령제약 주식회사 안정성이 개선된 복합제제
AR089765A1 (es) 2012-01-23 2014-09-17 Bayer Oy Un sistema para el suministro de un farmaco

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4780319A (en) * 1985-07-08 1988-10-25 Merck & Co., Inc. Organic acids as catalysts for the erosion of polymers
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
US4915954A (en) * 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
DE9015551U1 (pt) * 1990-11-14 1992-03-12 Roehm Gmbh, 6100 Darmstadt, De
US5422121A (en) * 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
US5358502A (en) * 1993-02-25 1994-10-25 Pfizer Inc PH-triggered osmotic bursting delivery devices
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
US20020169145A1 (en) * 1998-10-14 2002-11-14 Rajen Shah Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
DE10012555A1 (de) * 2000-03-15 2001-09-20 Merck Patent Gmbh Glucocorticoide in einer Modified Release-Formulierung
US6761895B2 (en) * 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof

Also Published As

Publication number Publication date
CA2478425A1 (en) 2003-09-12
EP1480623A1 (de) 2004-12-01
RU2004127193A (ru) 2005-09-10
WO2003074034A1 (de) 2003-09-12
JP2005526739A (ja) 2005-09-08
AU2003218701A1 (en) 2003-09-16
US20050203186A1 (en) 2005-09-15
DE10209979A1 (de) 2003-09-25
NO20044132L (no) 2004-09-29
PL372720A1 (en) 2005-07-25

Similar Documents

Publication Publication Date Title
BR0308229A (pt) Medicamentos contendo ingredientes ativos que diminuem o nìvel de colesterol com liberação do ingrediente ativo de tempo tardio
BRPI0516718B8 (pt) formulação de liberação modificada de ibuprofeno fornecendo liberação imediata e prolongada do fármaco
EA200800056A1 (ru) Каннабиноидный активный фармацевтический ингредиент для лекарственных форм
BR9908488A (pt) Composição farmacêutica de topiramato
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
BRPI0408999A (pt) comprimidos prensados de multiparticulados de liberação oral prolongada
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
SG157406A1 (en) Oral medicament for the modified release of at least one active principle, in multi-microcapsule form
BRPI0513300A (pt) forma farmacêutica oral, protegida frente ao abuso, contendo (1r, 2r)-3-(3-dimetilamino-1-etil-2-propil)-fenol
BR0314943A (pt) Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes
BR0313424A (pt) Forma de dosagem e processo para a preparação de uma forma de dosagem
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
NO20024586L (no) FremgangsmÕte og preparat for prevensjon av hormoninduserte ugunstige virkninger
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
FR2878161B1 (fr) Forme medicamenteuse orale, solide et concue pour eviter le mesusage
AR033688A1 (es) Composicion parenteral reconstituible
UA92498C2 (ru) Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм
WO2006108692A3 (en) Dosage form for oral administration of a vitamin
BRPI0414500A (pt) formulação farmacêutica composição para tratar uma infecção vaginal, e, métodos para tratar uma infecção vaginal, para estabilizar uma formulação de clindamicina, para tratar ou prevenir uma recorrência de uma infecção vaginal em uma paciente e para tratar condições vaginais
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
BRPI0513417A (pt) composição farmacêutica estável, usos de um poliol, e de uma composição, processo para preparar uma composição farmacêutica, e, método para tratar uma condição responsiva à administração de uma anti-histamina
ATE410152T1 (de) Therapeutisches system mit amoxicillin und clavulansäure
BRPI0414518A (pt) composições farmacêuticas e métodos compreendendo combinações de derivados de 2-alquilideno-19-nor-vitamina d e hormÈnio paratireoidiano
BRPI0410374A (pt) composição farmacêutica que compreende valsartano

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]